The effects of CXCL5 inhibition on fasting blood glucose were different between the current and previous studies, which might be related to different dosages and duration of the antibody treatment as well as the different age and different models of the experimental animals (db/db type 2 diabetic mice and STZ-induced type 1 diabetic mice). This evidence concerns the gene CXCL5 and type 1 diabetes mellitus.